FDA Approves Multi-Dose Vial of Thiotepa for Breast and Ovarian Cancer

Tepylute for breast, ovarian cancer launched in US

Tepylute (thiotepa), a chemotherapy medication from Shorla Oncology that was approved last year for treating certain breast and ovarian cancers, has launched in the U.S. Given via infusions into the bloodstream by a healthcare provider, Tepylute is a liquid formulation of thiotepa, a standard chemotherapy that’s been used to treat cancer for decades. The formulation initially approved by the FDA came in single-dose vials, but the regulators rece…

Ready-to-Dilute Thiotepa Approved for Breast and Ovarian Adenocarcinomas

A ready-to-dilute formulation of thiotepa has been approved by the FDA for use in breast and ovarian cancers.

FDA Approves Ready-to-Dilute Tepylute for Breast and Ovarian cancer

The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ovarian cancers.

FDA Approves Multi-Dose Vial of Thiotepa for Breast and Ovarian Cancer

The FDA approved a ready-to-dilute formulation of thiotepa in a multi-dose vial for the treatment with breast and ovarian cancer.